公开(公告)号：US20180353583A1

公开(公告)日：2018-12-13

申请号：US16109406

申请日：2018-08-22

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/74 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/30 ,  C07K16/28 ,  A61K35/17 ,  A61K38/00

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/34 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180344825A1

公开(公告)日：2018-12-06

申请号：US16054503

申请日：2018-08-03

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/74 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/30 ,  C07K16/28 ,  A61K35/17 ,  A61K38/00

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/34 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170165337A1

公开(公告)日：2017-06-15

申请号：US15374054

申请日：2016-12-09

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/725 ,  C12N15/115 ,  C07K7/06 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/34 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170080070A1

公开(公告)日：2017-03-23

申请号：US15357757

申请日：2016-11-21

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sara KUTSCHER

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  C07K14/725 ,  C07K14/435 ,  C07K14/74

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C07K2317/70 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20240350602A1

公开(公告)日：2024-10-24

申请号：US18759376

申请日：2024-06-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/08 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/08 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K14/70539 ,  C07K16/2833 ,  C12N5/0638 ,  C12N15/115 ,  A61K2039/5158 ,  C07K2319/00 ,  C12N2310/16 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/51 ,  C12N2501/515

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240285738A1

公开(公告)日：2024-08-29

申请号：US18647775

申请日：2024-04-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/00 ,  A61K39/39 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115

CPC classification number: A61K39/0011 ,  A61K39/39 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/572 ,  C07K2317/34 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230031307A1

公开(公告)日：2023-02-02

申请号：US17853334

申请日：2022-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  A61K51/10

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US20220323501A1

公开(公告)日：2022-10-13

申请号：US17837807

申请日：2022-06-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  A61K35/16 ,  A61K39/39

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220023404A1

公开(公告)日：2022-01-27

申请号：US17502185

申请日：2021-10-15

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K7/00 ,  A61K38/04 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  A61K35/17 ,  C07K7/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20220016227A1

公开(公告)日：2022-01-20

申请号：US17492112

申请日：2021-10-01

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  A61K38/04 ,  C07K7/06 ,  C07K7/00 ,  C07K7/08 ,  A61K35/17 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.